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(1) conception and design of the study; RJ, RPM, KR designed the study. an important complication of cirrhosis. [4, 5] Hyperammonemia is a feature of liver failure and over the past 120 years many studies have demonstrated incontrovertibly its central role in the pathogenesis of HE. [6, 7] The mechanism of ammonia-induced HE is hypothesised to be through induction of astrocytic osmotic stress swelling induced by glutamine derived from ammonia detoxification by the action of glutamine synthase. [4, 5] More recently, it has been shown that ammonia itself and/or the resulting of cell swelling can initiate a cascade of pathological events such as oxidative stress, resulting in RNA oxidation-and nitrosative stress, leading to nitration of critical proteins. [8] Many studies have indicated that human HSC, like astrocytes share similar markers when activated indicating that they belong to a similar mesodermal origin. [9] [10] [11] [12] Both cell types are characterised by a large cytokine repertoire including NFkB-induced pro-inflammatory cytokines. [13] [14] [15] [16] Previous work showed that rat HSCs express glutamine synthetase leading to our hypothesis that excess ammonia may therefore produce deleterious effects on the activity and function of primary human HSC as it does in astrocytes. [17] Following acute or chronic liver injury, HSCs undergo phenotypic transformation from "quiescent" (non-proliferating and non-contractile) to "activated" (promitogenic, [28, 29] in BDL rats was associated with a negative modulation of HSC activation and in the reduction of portal pressure.
Materials & Methods
Please refer to the Supplementary Materials and Methods, and Information section for more detailed descriptions.
In vitro studies in human HSC
Primary Human HSCs (hHSC) were isolated from wedge surgical sections of liver normal liver tissue, obtained from patients undergoing surgery in the Royal Free
Hospital after giving informed consent (EC01.14-RF). Cells were isolated according to Mederacke et al., [30] with the relative modifications for human liver. [31] Briefly, 10 g of total human liver tissue was digested with 0.01% Collagenase, 0.05% Pronase and 0.001% DNase I without performing perfusion. The homogenate was filtered through a 100µm cell strainer and the flow-through was centrifuged at 50xg
for 2 minutes at 4°C. After washing the supernatant, gradient centrifugation was performed at 1400xg for 17 minutes at 4°C using an 11.5% Optiprep gradient.
Finally, the interface was collected and washed. Purity of hHSC was established by detection of CD140b (PDGFRbeta), CD29 (Integrin beta 1) and Cytoglobin (CYGB).
The obtained HSCs were cultured in RPMI supplemented with 20% foetal bovine serum (FBS), GLUTAMAX, nonessential amino acids 1X, 1.0 mM sodium pyruvate, 1X antibiotic-antimycotic (all Life Technologies), referred to as complete HSC medium hereinafter. Experiments described in this study were performed on hHSC of at least three independent cell preparations between passage 3 and 8.
Treatment: Cells were seeded (density 26x10 Animals were sacrificed on the 5 th day of treatment.
(ii) In a second experimental protocol, the effect of the ammonia-lowering agent OP on ammonia-induced portal hypertension was investigated. Four weeks after BDL or sham operation, rats were randomized into three groups: sham-operated rats receiving saline (i.p.) (n=18) twice a day for the experimental period of 5 days; BDL rats (n=20) were administered i.p. saline twice a day for 5 days; a further group of BDL rats (n=11) received i.p. injection of OP 0.3 g/kg twice a day for 5 days.
Between weeks 4 and 5, following anesthesia (2% isofluorane), rats from each group underwent assessment of mean arterial pressure via isolation and cannulation of the right carotid artery. In addition, portal pressure was measured by direct cannulation of the main portal vein. All measurements were transduced to a Powerlab (4SP)
linked to Chart v5.0.1 software. The mean of three readings taken one minute apart was recorded. Liver tissue was harvested and snap-frozen for storage at 80°C until analyzed.
Statistical analysis
Results are expressed as mean values ± SEM and compared using one-way analysis of variance followed by Dunnet's or Tukey's multiple comparison post hoc tests, where appropriate. P values ≤0.05 were considered significant.
In vivo experimental data were analysed by t tests and Mann-Whitney U test as appropriate; P <0.05 was considered statistically significant. Results are presented
as mean values ± SEM using GraphPad Prism software (GraphPad, La Jolla, CA).
Results

Ammonia reduces cell proliferation and metabolism in human Hepatic Stellate
Cells in vitro in a dose dependent manner
Human HSC treated with different concentrations of ammonia for 72 hours showed a significant inhibition in cell proliferation (BrdU assay) and metabolic activity (MTS assay) (Fig. 1A) . Furthermore, long term treatment of hHSC with ammonia did not cause cell death as assessed by deploying the Cell Death Detection ELISA (Fig.   1B) . Also, these ammonia-induced effects coincided with strong alterations in cellular morphology in a dose-dependent manner as observed by light microscopy (Fig. 1C) .
Treatment with ammonia led to drastic changes in cell morphology with the appearance of a spindle-like fibroblast phenotype, and signs of deregulation of the endo-lysosomal compartment as assessed by Neutral Red, a dye retained by the lysosomes (Fig. 1C) . As demonstrated in Supplementary Fig.1 human HSC express GS at the mRNA and protein level. Pretreatment of cells with MSO, a biochemical inhibitor of GS, followed by exposure to ammonia did not further inhibit proliferation and metabolic activity in comparison to MSO treatment only (Supplementary Fig.   1 ).
Ammonia induces alterations in cytoplasmic stress, which coincides with changes in cellular metabolism/function and actin cytoskeleton architecture
The morphological changes observed by light microscopy were further characterised by performing ultrastructural studies. Ammonia caused a dramatic dose-dependent change in the cytosol with ER enlargement and marked presence of translucent vacuoles. Neither mitochondrial alterations nor presence of autophagic structures (characterised by double membranes) were observed ( Fig. 2A) . Of importance is the fact that when ammonia-rich medium was removed and cells were replenished with complete medium both cell proliferation and metabolic activity were restored ( Fig.   2B) , thus supporting the idea that the observed effect of ammonia is transient.
Moreover, ammonia-treated hHSC cultured on collagen gels showed a significant ability to contract (Fig. 2C, 2D ) when compared to control. This effect was observed as soon as three hours of ammonia treatment and appeared to be still sustained after 24 hours which coincided with the previously observed morphological changes (Fig. 2E) . Furthermore, long-term treatment with ammonia (72 hours) induced a dose-dependent re-organization of filamentous actin in the cytoskeleton when TRICT-Phalloidin staining was employed. Re-organization of the F-actin network coincided with the presence of translucent vacuoles in a dose depended manner (Fig. 2F ).
Ammonia induces ER enlargement
As the ultrastructural study showed a marked ammonia-dependent dysregulation and enlargement of the ER compartment, we then further evaluated the status of ER stress. To this end, cells were cultured and treated with ammonia as previously described, for 1, 3 up to 24 hours, followed by qPCR for two ER stress marker genes i.e. ATF6 and XBP1. Both, mRNA expression levels were up-regulated in a dose-and time dependent manner with a marked up-regulation after 3 hours for all ammonia concentrations tested, which decreased again after 24 hours of treatment (Fig. 3A) .
Moreover, pre-treatment with TUDCA, a bile salt derivate with ER-chaperone properties, alleviated the previously shown increase in ammonia-induced ATF6 and XBP1 mRNA expression after 3 hours. Prolonged treatment with ammonia for 72 hours, altered the ER dynamics with a strong peri-nuclear accumulation of ER-Tracker™ Red dye and the presence of cytoplasmic vacuoles with increasing ammonia concentrations (Fig. 3C) .
Hyperammonemia induces ROS production in hHSC
As ER stress is associated with or/and leads to ROS formation, the possibility that ammonia stimulates ROS production was assessed. Prolonged treatment of cells with ammonia for up to 72 hours showed a gradual development of ROS as detected by the presence of cytosolic carboxy-DCF (Fig. 4A) . The development of ammoniainduced ROS production was further quantitatively measured as described previously, [34] and confirmed that primary hHSCs treated with ammonia produced significant ROS (Fig. 4B) . Next, cells treated with ammonia for different time points
showed a strong increase in mRNA expression of Superoxide dismutase 2 (SOD2) after 3 hours, which was sustained at 24 hours of ammonia treatment (Fig. 4C) .
Moreover, pre-treatment with N-acetyl cysteine (NAC), a known ROS scavenger, showed no impact on the previously observed increase in SOD2 mRNA expression after 3 hours of ammonia treatment. In contrast, pre-treatment with NAC followed by ammonia treatment for 24 hours, almost completely abolished ammonia-induced SOD2 mRNA expression.
Ammonia alters the pro-fibrogenic/pro-inflammatory profile in hHSC
Next, the possibility that ammonia-induced ROS formation causes alterations in HSC-related activation markers and pro-inflammatory genes was investigated. As shown in Fig. 5A , ammonia was shown to significantly increase α-SMA protein expression. At 300µM ammonia, vimentin (an important intermediate filament)
synthesis was increased. Both Myosin IIa (that plays a key role in HSC contraction)
and Myosin IIb (implicated in HSC activation), were significantly modulated by increasing concentrations of ammonia. A dose-dependent response to ammonia was also observed in P-38 MAPK expression. Furthermore, PDGFR-β, important in HSC cell proliferation, showed a significant up-regulation under influence of ammonia, whereas Collagen type I showed a tendency to increase by ammonia, albeit these effects were not statistically significant (Fig. 5A) . Furthermore, ammonia induced a strong and significant up-regulation of MMP2 mRNA expression, whereas mRNA expression of TIMP1 was down-regulated (Fig. 5B) . Moreover, pro-inflammatory
Interleukin-1β mRNA expression was significantly induced when hHSC were treated with ammonia 300 µM for 72 hours (Fig. 5C) , whereas ammonia at 50 µM and 100 µM doses significantly up-regulated Interleukin 6 mRNA expression level. By contrast, ammonia did not modify Interleukin 8 mRNA expression in HSC (Fig. 5C) .
In vivo study I: Bile duct ligation and ammonia treatment modifies HSC cell biology in vivo
In a first set of in vivo experiments the effect of hyperammonemia on HSC-related signalling pathways in whole liver tissue was investigated. As previously described [13] ammonia concentrations were noted to be significantly elevated in BDL rat plasma compared to sham-operated rats (149.3µmol/L±51.1 vs.
107.4µmol/L±23.2, P < .05). Plasma ammonia levels further increased when animals
were fed an amino acid-rich (AAs) diet in combination with BDL surgery (199.1µmol/L±43.6 vs. 149.3µmol/L±51.1, P < .05) (Fig. 6A) . More importantly, plasma ammonia levels decreased significantly when BDL-AAs-fed animals were treated with OP (123.9µmol/L±16.1 vs.199.1µmol/L µM±43.6, P < .001) (Fig. 6A) .
These significant changes in ammonia plasma levels were correlated with alterations in portal pressure which was significantly higher in BDL rats and BDL-AAs-fed animals compared to sham (Supplementary Fig. 2) . Expectedly, as the animals in the OP group were only treated for 5-days, no differences in collagen accumulation, assessed by Picrosirius Red staining, was demonstrated between BDL-AAs-fed animals and BDL-AAs-fed OP treated animals (Supplementary Fig. 3 ).
Of note, the observed changes in haemodynamics post OP treatment coincided with a marked decrease in protein expression of HSC-related activation markers (Fig.   6B ). More specifically, BDL in combination with hyperammonaemia (AAs diet)
showed a significant increase in Myosin IIb, Collagen type I, and PDGF-Rβ protein expression in comparison to BDL. In contrast, treatment with OP abrogated the strong effect of hyperammonaemia on BDL rat livers in relation to all HSC-related activation markers tested (Fig. 6B) .
As ammonia-induced ER enlargement in hHSCs in vitro (Fig. 3A) the expression of ER stress-markers (CHOP and BiP) was evaluated in vivo. CHOP protein expression was increased in BDL and BDL-AAs-fed animals in comparison to sham-operated animals, with a minor but significant down regulation in BDL-AAs-fed and OPtreated animals (Fig. 6C) . In contrast, BiP protein expression was significantly down regulated in all BDL treated animals in comparison to Sham-operated rats, whereas OP treatment significantly prevented BiP protein down regulation in comparison to BDL-AAs-fed animals (Fig. 6C) . Overall, these data indicate that OP treatment abolishes ammonia-induced ER-stress, with associated reduced HSC activation and consequent reduction in portal pressure.
In vivo study II: Treatment with OP improves portal pressure through reduction in nitrosative stress
As described above, in the second in vivo study, ammonia concentrations were noted to be significantly elevated in BDL rat plasma compared to sham-operated rats (182±12.8 vs. 62.51±6.2 µM, P < .0001), and this decreased significantly following treatment with OP (83.8±16.3 µM, P < .0001). These significant changes in plasma ammonia were correlated with alterations in portal pressure, which was significantly higher in BDL rats compared to sham (14±0.6 vs.5.5±0.3 mmHg, P < .0001) (Fig.   7A ). Ammonia lowering through administration of OP resulted in a significant reduction in portal pressure compared to BDL -saline treated rats (11±0.3 mmHg, P < .01). Mean arterial pressure (MAP) was significantly higher in sham rats compared with BDL animals (105±2.3 vs 80±2.9 mmHg, P < .001). Following OP therapy, there was no significant change in MAP observed between BDL saline and OP treated rats (Fig. 7A) . As a consequence of the ammonia-induced inflammatory and oxidative pathways observed in HSCs in vitro, and the effect of hyperammonemia on HSCrelated activation markers in vivo, the impacts on nitrosative stress was also assessed in whole liver tissue. When compared to sham-operated rats, there were significant increases in iNOS protein expression in BDL rats (Fig. 7B) . Treatment with OP significantly reduced iNOS expression when compared to BDL control animals. Moreover, 3-NTyrosine expression (as an indication of increased nitrosative stress), was also significantly up-regulated in BDL treated animals compared to sham animals and this was reduced significantly following treatment with OP (Fig.   7C ). eNOS protein expression was significantly increased in BDL rats compared to sham animals (as we previously described [34] ) and this remained statistically unchanged after OP therapy (Fig. 7C) . More importantly, a significant reduced eNOS enzyme activity was observed in BDL rat liver compared to sham-operated animals, which was restored to near normal levels after OP therapy. Furthermore, the expression of Caveolin-1 (an intracellular eNOS inhibitor) was found to be significantly higher in BDL livers compared to sham rats. In contrast, in BDL animals treated with OP, Caveolin-1 expression showed a significant down regulation in comparison to BDL rats (Fig. 7C) .
Discussion
The results of this study reveal, for the first time, that pathophysiologically relevant concentrations of ammonia produce marked deleterious consequences on HSCs in vitro and in vivo including: changes in endoplasmic reticulum dynamics and increase cellular oxidative stress, which are transient and can be prevented by intervention, providing therapeutic opportunities. Reduction in ammonia concentration using the ammonia-lowering drug OP, for a short term treatment of 5 days, resulted in a down regulation of HSCs activation markers in BDL rats that coincided with a significant reduction in portal pressure, providing a potential novel strategy to treat portal hypertension.
The first set of experiments clearly showed that increasing concentrations of ammonia were associated with marked structural and functional changes of hHSCs.
This was not associated with any evidence of cell-death and notably these effects were reversible when ammonia was removed from the medium and cells were allowed to recover. Hence, providing the first indication that ammonia-induced dysfunction of HSCs is reversible. In accordance with prior observations in rat HSCs [17] , human HSCs also express GS. Interestingly, although GS gene expression remained unaffected by increasing concentrations of ammonia, a significant reduction in protein levels was observed. The mechanism(s) of this reduction is not clear but may be a consequence of reduced detection or breakdown, as ammonia has been shown to nitrosylate GS in astrocytes. [35] [36] [37] These changes in functionality as observed in this study were closely associated with dose-dependent morphological alterations, as assessed by light and transmission electron microscopy. On light microscopy, cells appeared longer, spindly and also presented marked vacuolization. These alterations were further confirmed by ultra-structural analysis as evidenced by dose-dependent cytoplasmic vacuolization, with no significant nuclear alterations. Whilst the treatment of astrocytes with ammonia has been shown to induce mitochondrial swelling [38] and autophagy, in this study, ammonia induced cytoplasmic vacuolization in hHSCs was without the formation of autophagic bodies or alterations in mitochondrial structure.
Indeed, ammonia-induced autophagy has been shown to be cell type and context dependent. [39, 40] These morphological changes coincided with modifications in the actin cytoskeletal architecture such as the re-organization in filamentous actin and a significant up-regulation in α-SMA and myosin IIa protein expression, after a prolonged treatment with ammonia. Furthermore, ammonia induced contraction of hHSC, indicating that ammonia strongly affects actin, which is important in maintaining HSC cell integrity and function.
In this study, evidence of marked ER swelling and vacuolisation was observed. The ER uses its protein folding status as a signal to orchestrate downstream apoptotic or adaptive responses and the ER is known as a key player in the process of liver damage. [41] Moreover, it is known that ER stress can induce activation of primary hHSC and induce its morphological changes and dysfunction through induction of autophagy. [42] In this study, ammonia induced, in a time dependent manner, ER stress markers, which coincided with up-regulation of HSC activation markers but without affecting apoptosis and autophagy. Moreover, the co-involvement of ammonia-induced ER stress in hHSC was further demonstrated by using Tauroursodeoxycholic Acid (TUDCA) [40] known to exert protection from liver injury by inhibiting ER-stress.
In order to determine the effectors of these functional and morphological changes induced by ammonia, our study further focused on the development of oxidative Overall, the ammonia-induced ROS production affects the mRNA and protein expression levels of HSC activation markers and several pro-inflammatory interleukins. It was therefore notable that the protein expression for p38MAP kinase was increased by ammonia in the hHSC, which is a key signal transduction mediator of inflammation in many cell types. [47] Previous studies have indicated a similar upregulation of gene and protein expression of p38MAP kinase in astrocytes and also in neutrophils after exposure to ammonia. In fact, inhibition of p38MAP kinase in neutrophils reversed this ammonia-induced functional derangement. [32, 48, 49] In order to determine whether this observation in vitro could be translated in vivo, we chose to study BDL animals that are spontaneously mildly hyperammonemic.
Further exaggeration of hyperammonemia in these animals using a hyperammonemic diet resulted in an additional increased protein expression of HSC activation markers such as Myosin IIa and IIb, αSMA, PDFRβ and Collagen-1. These HSC markers were significantly reduced following treatment with OP, an ammonia lowering drug which has previously been shown to lower plasma ammonia concentrations. [28] These data provide direct in vivo evidence that hyperammonemia induces HSC activation and that lowering ammonia concentration reduces this activation.
In order to test whether ammonia reduction is a target for the treatment of portal hypertension, we chose to study the BDL animal model, which is known to exhibit hyperammonemia, increased portal pressure and is clinically relevant. [28] In this model, the effect of ammonia reduction on eNOS activity in the brain was previously investigated using OP. The results showed reduction in brain water and improved brain eNOS activity through effects upon eNOS regulators. [50] The same model was used in this study to examine the effect of OP on portal pressure. Reduction in ammonia with OP was associated with a significant and marked reduction in portal pressure to values that were not significantly different to control animals without any significant change in the mean arterial pressure. This improvement in portal pressure was associated with a reduction in markers of oxidative and nitrosative stress such as iNOS and 5-nitrotyrosine, and induction in eNOS enzyme activity.
In conclusion, the data presented in this paper provide the first indication that show means of three independent values ± SD. *P < .05, **P < .01 and ***P < .001
vs. corresponding values of serum free medium (SFM). values ± SD. *P < .05, **P < .01 and ***P < .001 vs. corresponding values of SFM. showed an additional significant increase in Myosin IIb, Collagen type I and PDGF-Rβ protein expression in comparison to BDL-induced fibrosis (**P < .01 and ***P < .001). In contrast, treatment with OP, abrogated the strong effect of AAs-fed BDL on all HSC-related activation markers (*P < .05, **P < .01 and ***P < .001). (C) CHOP protein expression was increased in BDL and BDL-AAs-fed animals with a minor but significant down regulation in BDL-AAs-OP-treated animals (*P < .05 vs BDL -AAsfed). BiP protein expression was significantly down regulated in all BDL treated animals in comparison to Sham-operated rats, whereas OP treatment significantly prevented BiP protein down regulation in comparison to BDL-AAs-fed animals (*P <
.05 vs BDL -AAs-fed). Protein expression of eNOS was significantly increased in BDL rats compared to sham animals (***P < .001) and remained unchanged after OP therapy. A significant reduced eNOS activity was observed in BDL rats compared to sham-operated animals (*P < .05) and this was restored to near normal levels after OP therapy (*P < .05 vs BDL). Caveolin-1 expression was upregulated in BDL livers compared to sham rats (***P < .001) and was downregulated upon with OP treatment (**P < .01
vs. BDL).
